August 2024
Notice of Allowance by Korean Intellectual Property Office (KIPO) : METHODS OF DIAGNOSING AND TREATING LUNG CANCER
July 2024
Notice of acceptance by the Australia Patent Office: METHODS OF DIAGNOSING AND TREATING LUNG CANCER
March 2024
Professor Aaron Ciechanover has joined Savicell’s Advisory Board. He is a Distinguished Research Professor in the Rappaport Faculty of Medicine at the Technion, and is the 2004 Nobel laureate in Chemistry. In addition, he founded the Rappaport Technion Integrated Cancer Center (RTICC).
Professor Ciechanover was awarded the 2004 Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation, the process by which cells dispose defective or excess proteins that are no longer useful. Protein degradation disorders are responsible for various diseases. The discovery led to the development of several successful anti-cancer drugs including Velcade® and an entire family of Immunomodulatory drugs. The ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders.
Prof. Ciechanover has served as Director of the Rappaport Family Institute for Research in the Medical Sciences; the founding Director of the Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering; head of the David and Janet Polak Center for Cancer Research and Vascular Biology; Vice Chancellor of the Guangdong Technion Israel Institute of Technology; and Founder and Co-director of the RTICC, which integrates the Technion’s renowned engineering capabilities with oncology care and research. He also conceived of and established the Bruce and Ruth Rappaport Cancer Research Center.
In addition to the Nobel Prize, Prof. Ciechanover has received numerous awards including the Albert Lasker Award in Basic Medical Research, 2002 EMET Prize, and 2003 Israel Prize for Biology. He has published more than 200 articles and book chapters. His contributions to science and humanity have been recognized with honorary doctorates from more than 50 universities.
Ciechanover is member of the Israeli National Academy of Sciences and Humanities, The European Molecular Biology Organization (EMBO), the American Academy of Arts and Sciences (Foreign Fellow), the American Philosophical Society, the National Academies of Sciences (NAS) and Medicine (NAM) of the USA (Foreign Associate), the Pontifical Academy of Sciences at the Vatican, the Chinese Academy of Sciences (CAS; Foreign Member), the Russian Academy of Sciences (Foreign Member), and the German Academy of Sciences (Leopoldina).
September 2023
A case report was published in the Open Journal of Clinical & Medical Case Reports: Liquid ImmunoBiopsy-based detection of early stage lung cancer in a volunteer subject recruited as a ‘healthy donor’ of a lung cancer diagnosis clinical trial study: A case report:
https://jclinmedcasereports.com/articles/OJCMCR-2110.pdf
September 2023
Granted patent by the Japan Patent Office titled: METHODS OF DIAGNOSING AND TREATING LUNG CANCER on September 22, 2023.
April 2023
The United States Patent and Trademark Office (USPTO) granted patent titled: METHODS OF DIAGNOSING AND TREATING LUNG CANCER on April 4, 2023
February 2023
Savicell's latest lung cancer clinical study results were published in Respiratory Research journal
Notice of Allowance by Korean Intellectual Property Office (KIPO) : METHODS OF DIAGNOSING AND TREATING LUNG CANCER
July 2024
Notice of acceptance by the Australia Patent Office: METHODS OF DIAGNOSING AND TREATING LUNG CANCER
March 2024
Professor Aaron Ciechanover has joined Savicell’s Advisory Board. He is a Distinguished Research Professor in the Rappaport Faculty of Medicine at the Technion, and is the 2004 Nobel laureate in Chemistry. In addition, he founded the Rappaport Technion Integrated Cancer Center (RTICC).
Professor Ciechanover was awarded the 2004 Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation, the process by which cells dispose defective or excess proteins that are no longer useful. Protein degradation disorders are responsible for various diseases. The discovery led to the development of several successful anti-cancer drugs including Velcade® and an entire family of Immunomodulatory drugs. The ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders.
Prof. Ciechanover has served as Director of the Rappaport Family Institute for Research in the Medical Sciences; the founding Director of the Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering; head of the David and Janet Polak Center for Cancer Research and Vascular Biology; Vice Chancellor of the Guangdong Technion Israel Institute of Technology; and Founder and Co-director of the RTICC, which integrates the Technion’s renowned engineering capabilities with oncology care and research. He also conceived of and established the Bruce and Ruth Rappaport Cancer Research Center.
In addition to the Nobel Prize, Prof. Ciechanover has received numerous awards including the Albert Lasker Award in Basic Medical Research, 2002 EMET Prize, and 2003 Israel Prize for Biology. He has published more than 200 articles and book chapters. His contributions to science and humanity have been recognized with honorary doctorates from more than 50 universities.
Ciechanover is member of the Israeli National Academy of Sciences and Humanities, The European Molecular Biology Organization (EMBO), the American Academy of Arts and Sciences (Foreign Fellow), the American Philosophical Society, the National Academies of Sciences (NAS) and Medicine (NAM) of the USA (Foreign Associate), the Pontifical Academy of Sciences at the Vatican, the Chinese Academy of Sciences (CAS; Foreign Member), the Russian Academy of Sciences (Foreign Member), and the German Academy of Sciences (Leopoldina).
September 2023
A case report was published in the Open Journal of Clinical & Medical Case Reports: Liquid ImmunoBiopsy-based detection of early stage lung cancer in a volunteer subject recruited as a ‘healthy donor’ of a lung cancer diagnosis clinical trial study: A case report:
https://jclinmedcasereports.com/articles/OJCMCR-2110.pdf
September 2023
Granted patent by the Japan Patent Office titled: METHODS OF DIAGNOSING AND TREATING LUNG CANCER on September 22, 2023.
April 2023
The United States Patent and Trademark Office (USPTO) granted patent titled: METHODS OF DIAGNOSING AND TREATING LUNG CANCER on April 4, 2023
February 2023
Savicell's latest lung cancer clinical study results were published in Respiratory Research journal
https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-023-02358-w
October 2022
The United States Patent and Trademark Office (USPTO) issued a Notice of Allowance on Patent Application Titled: METHODS OF DIAGNOSING AND TREATING LUNG CANCER. Notice of Allowance is issued after an examiner determines that a patent application satisfies the requirements for patentability. This continues to build our patent estate in the USA
July 2022
Received a clean patent freedom to operate (FTO). “A freedom to operate opinion (FTO) is a legal opinion from a qualified intellectual property attorney that concludes a proposed commercial product or process may be made, used, sold, or offered for sale without infringing another party’s intellectual property rights. Although there is no legal requirement for a company to obtain an FTO opinion before taking a new product, process, or service to market, obtaining one can be very beneficial as a preemptive measure to aid in defending a company in patent litigation against assertions of willful infringement and exposure to treble damages. By minimizing litigation risks, an FTO opinion can also minimize potential investors’ concerns about the marketability of the company’s product, process, or service*.”
*Dickinson-Wright.com
July 2022
The Brazilian Patent Office has allowed our patent (title below). Official allowance notification was issued.
Title: A METHOD OF MEASURING A METABOLIC ACTIVITY (MA) OF A CELL, AN EX-VIVO METHOD OF DIAGNOSING A DISEASE ASSOCIATED WITH A MODIFIED
METABOLIC ACTIVITY IN A SUBJECT-IN-NEED THEREOF, AN EX-VIVO METHOD OF OPTIMIZING DISEASE TREATMENT, AN EX-VIVO METHOD OF MONITORING
DISEASE TREATMENT IN A SUBJECT AND AN EX-VIVO METHOD OF IDENTIFYING AN AGENT CAPABLE OF ALTERING A METABOLIC ACTIVITY OF CELLS
September 2021
In a clinical trial (n=245), an improved test protocol was applied and resulted in increased test accuracy. Specificity of the test increased to 97% and test sensitivity increased to 97% in lung cancer stage I, by using the improved protocol. Study summary is in the publication section.
August 2021
Savicell finalized collaboration agreement with Orgenesis Inc. (NASDAQ: ORGS)
to use Savicell’s patented immunometabolism platform to develop and validate kits for QC and/or monitoring purposes in manufacturing and processing of Orgenesis’ cells & gene therapies.
October 2020
Initiate a clinical study using Savicell’s ImmunoBiopsy™ platform to evaluate the T cells reactivity to SARS COV 2.
clinicaltrials.gov/ct2/show/NCT04573348
March 2020
Yair Briman appointed to Advisory Board
Mr. Briman is a seasoned professional with over 25 years of global leadership experience in the digital healthcare industry. From 2006 through 2019, Mr. Briman served in various senior executive roles at Philips Healthcare, including as Vice President & General Manager, Global Imaging Clinical Applications and most recently as CEO of Philips’ Healthcare Informatics division. In this role he oversaw global informatics operations including HIS (healthcare information systems), EMR (electronic medical records), PACS (picture archiving and communication systems), Advance Visualization, Oncology Informatics, and Cardiology Informatics. During his tenure at Philips, Yair was responsible for sales, marketing and distribution, R&D, service, oversaw the completion and integration of numerous acquisitions, managed global supply chains, and managed over 3,000 employees worldwide. In 2013, Yair Co-founded and served as a board member of Sanara Ventures, a healthcare focused start-up incubator backed by Philips and Teva Pharmaceuticals, where he oversaw investments and supported the creation of 13 healthcare startups. Previously, Mr. Briman served as Vice President of R&D at Gigaspaces and as global manager of software development for Intel.
December 2019
Peter C. Gonze appointed to Advisory Board
A seasoned health care executive, Peter has over 40 years of leadership experience with Fortune 500 companies, small and mid-cap enterprises as well as start-ups. In senior executive roles he has built businesses in nonprescription pharmaceuticals, diagnostics products, biotechnology with a focus in immunotherapeutic technologies, and clinical research organizations. These include president of Averion International CORP., an international clinical research organization (CRO), President of Advanced immune Therapeutics (AITRx) specializing in translational immunology, COO of Unither Pharmaceutical INC, (NASDAQ: UTHR) focused on antibody based oncology therapeutics, Divisional Vice President at Abbott Diagnostics (NYSE:ABT), V.P. Business Development at J&J and Rhone Poulenc Rorer. With extensive experience working with development stage companies, both publicly held and private. Peter has served in Board positions where he has taken an active role advising management teams on business strategies to maximize stakeholder value. Leading an international clinical research organization (CRO) supporting global clinical trials for pharmaceutical, biotechnology and medical device companies. Peter has served in both executive and board roles with companies working in therapies ranging from oncology, cardiovascular, diabetes and medical diagnostics.
September 2018
Poster presentation on clinical results of early stage lung cancer study with Savicell's ImmunoBiopsy will be given at the International Congress of European Respiratory Society in Paris, France.September 13, 2016 15:31 ET
May 2018
Savicell's lung cancer clinical study results were published in Cancer Immunology and Immunotherapy
Cancer Immunology, Immunotherapy; May 2018
https://doi.org/10.1007/s00262-018-2173-5 ORIGINAL ARTICLE
September 2016
Online Disruptive Technologies Announces Asian Patents and Initial Test Results
LAS VEGAS, NEVADA--(Marketwired - Sept. 13, 2016) - Online Disruptive Technologies, Inc. (OTC PINK:ONDR) (the "Company") is pleased to announce that its majority owned Israeli subsidiary, Savicell Diagnostic Ltd. ("Savicell"™), has received patent approval from the Chinese and Japanese patent offices effective as of May 12, 2016 and July 29th, 2016 respectively. Title: "METHODS OF MONITORING AND ANALYZING METABOLIC ACTIVITY PROFILES DIAGNOSTIC AND THERAPEUTIC USES OF SAME". The technology has now received intellectual property protection with a patent approved in the United States, China and Japan. Furthermore, the patent process is ongoing in several other countries.
The Savicell™ platform is a blood test designed for the early detection of disease. It is a broad platform with applications for cancer, autoimmune diseases, and infectious diseases. While our focus initially is on early diagnosis of disease, we believe our technology may have additional applications in drug response monitoring for therapies that impact immune response. Immunotherapy, both for treating cancer and autoimmune diseases, is an example where metabolic shift profiles could indicate response to drug treatment.
Initially, Savicell is focused on the multibillion-dollar cancer diagnosis market. Savicell deploys Well-Shield™ technology, a Liquid ImmunoBiopsy™ diagnostic platform. In contrast to existing technologies that evaluate secretions of cancer cells, Well-Shield's ImmunoBiopsy platform receives data directly from the immune system. Importantly, Well-Shield is different in that it is a functional test measuring the metabolic activation profile of the immune system as an indicator of disease status. As an immune system test, it is inherently suited for early detection.
Disease intrusion and cell malformation, including cancer, are first detected by the immune system, which energizes to rid the body of the malignancy. The initial immune response to disease is intricate, deploying different metabolic pathways and subtypes of cells. The Well-Shield™ technology is designed to detect and interpret these differential metabolic responses.
The need for simpler and more efficient processes for cancer detection has incentivized some 38 companies in the USA to work on creating liquid biopsies. In a 2015 report, investment bank Piper Jaffray valued the potential market for liquid biopsies at $29 billion just in the United States.
Savicell conducted clinical work for tests specific to breast and lung cancers in multiple medical centers. We had encouraging early reviews of our breast cancer and lung cancer analyses, albeit on relatively small sample sizes. Specifically, we distinguished between breast cancer patients and healthy donors, and lung cancer patients and healthy donors, with high sensitivity and specificity of greater than 95% in both cancers. In addition, we were able to show that there is a metabolic profile difference between other breast disease donors and breast cancer donors and between chronic obstructive pulmonary disease donors and lung cancer donors.
Based on this early potential, Savicell decided to focus our resources on lung cancer as our lead product. We are working to increase the population size of the lung cancer clinical test and continue to fine-tune a predictive algorithm to identify lung cancer. Early results of this effort generated promising cross-validation of 72 donors from our clinical study. This cohort includes 36 diseased donors, together with a control group of 36 age- and sex-matched healthy donors. In practice this means that every lung cancer patient in the cohort was matched with a healthy donor of the same gender and similar age. This practice helps us control for sampling biases.
Cross-validation (CV) - we let the algorithm train on a large subset of labeled donors, and then let it make a prediction on a small subset of unlabeled donors that were not in the training set. This process is repeated several times until every donor in the cohort is given a prediction. While we are pleased with these promising results, please note that results can change as we increase the cohort size.
In the longer term, we plan to develop a screening test for lung cancer. However, our initial goal is to provide an additional tool for clinicians, designed to assist in the diagnosis of indeterminate nodules identified by imaging. The Well-Shield test is intended to help a clinician decide on invasive and/or non-invasive follow-up. It could help reduce the majority of the false positive results and reduce the number of unnecessary invasive procedures by more than 200,000 annually in the US (See footnotes (1) and (2)). As a result, Well-Shield's test could drive $3.6 billion in annual cost savings in the USA alone.
Footnotes: (1) Moving Beyond the National Lung Screening Trial: Discussing Strategies for Implementation of Lung Cancer Screening Programs Bernando H.L. Goulard, The Oncologist. 2013 Aug; 18(8): 941-946
(2) Assume 10 million patients screened and sensitivity and specificity of 92% and 75% respectively. Well-Shield may have higher or lower sensitivity and/or specificity.
Notice Regarding Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Forward-looking statements in this press release include that our technology is designed to be deployed for early detection of diseases; that our technology may have additional applications in drug response monitoring for therapies that impact immune response, that the Well-Shield™ technology is designed to detect and interpret differential metabolic responses. that Well-Shield could help reduce the majority of the false positive results and reduce the number of unnecessary invasive procedures by more than 200,000 annually in the US therefore could save $3.6 billion annually in the USA alone.; and that we have patent protection on our technology. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug and treatment discovery and development, which include, without limitation, the potential failure of development candidates to advance through clinical studies or demonstrate safety and efficacy in clinical testing; our ability to retain key employees; our ability to finance development; and our ability to satisfy the rigorous regulatory requirements for new medical procedures. Good results in small trials and among limited cases does not necessarily lead to the same good results for large numbers or in the general public. Competitors may develop better or cheaper alternatives to our products. Having patented technology does not guarantee that our patents may not be challenged, or that we may be infringing on the intellectual property of others. We may not be able to commercialize our product and even if we do, we may not realize any profit. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this press release to reflect events or circumstances after today's date. Readers should also refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.
December 16, 2015 14:11 ET
Online Disruptive Technologies Announces Approval to Perform Diagnostic Clinical Trials on Human Blood
LAS VEGAS, NEVADA--(Marketwired - Dec. 15, 2015) - Online Disruptive Technologies, Inc. (OTC PINK:ONDR) (the "Company") is pleased to announce that its majority owned Israeli subsidiary, Savicell Diagnostic Ltd. ("Savicell" ™), has received the approval of the Ethics Committee of the Institutional Review Board of the Rambam Health Care Campus to perform clinical trials on human blood for Savicell's blood test designed for the early diagnosis of lung cancer. The Rambam Health Care Campus is a 1,000-bed academic hospital serving the over 2 million residents of Northern Israel.
In addition, Savicell™ has received the approval of the Ethics Committee of the Institutional Review Board of the Meir Medical Center, also for human blood trials for lung cancer. This center represents a 717-bed hospital and serves as the central medical facility of the Sharon and Shomron area, serving a population of some 800,000 residents.
No further approvals are necessary to commence clinical trials for human blood tests for the detection of lung cancer at the Sourasky Medical Center or the Meir Medical Center. Savicell™ expects to expand its trials using blood supplied by these new sites during the month of December 2015.
Savicell™ has recently moved to a new, customized and larger lab in Haifa, Israel. The new facility will allow the company to handle an increased volume of testing and analysis.
Savicell™ is a company formed to commercialize a blood test uniquely designed for the early detection of diseases including cancer and auto-immune diseases.
Initially Savicell™ is focused on the multibillion-dollar cancer diagnosis market. Savicell™ deploys Well-Shield™ technology, an ImmunoBiopsy™ diagnostic platform. In contrast to existing technologies that evaluate secretions of cancer cells, Well-Shield's ImmunoBiopsy platform receives data directly from the immune system. Importantly, Well-Shield is different in that it is a functional test measuring the metabolic activation profile of the immune system as an indicator of disease status. As an immune system test it is inherently suited for early detection. The technology has intellectual property protection with a patent approved and published in the United States, with further international patent applications in process.
Disease intrusion and cell malformation, including cancer, are first detected by the immune system which energizes to rid the body of the malignancy. The initial immune response is intricate, deploying different metabolic pathways and subtypes of cells. A key function of immune system metabolic changes (glycolysis shifts) is to drive and control the effector function of the immune system. The effector ability to secrete disease-fighting cytokines (e.g. interferon gamma) is an example. The Savicell Well-Shield™ technology is designed to detect and interpret these differential metabolic responses.
Notice Regarding Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Forward-looking statements in this press release include that our unique technology is designed to be deployed for early detection of diseases; that we will expand our clinical trials on human blood this month; that we can handle an increased volume of analysis; and that we have patent protection on our technology. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development, which include, without limitation, the potential failure of development candidates to advance through clinical studies or demonstrate safety and efficacy in clinical testing; our ability to retain key employees; our ability to finance development; and our ability to satisfy the rigorous regulatory requirements for new medical procedures. Competitors may develop better or cheaper alternatives to our products. Having patented technology does not guarantee that our patents may not be challenged, or that we may be infringing on the intellectual property of others. We may not be able to commercialize our product and even if we do, we may not realize any profit. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this press release to reflect events or circumstances after today's date. Readers should also refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.
In the longer term, we plan to develop a screening test for lung cancer. However, our initial goal is to provide an additional tool for clinicians, designed to assist in the diagnosis of indeterminate nodules identified by imaging. The Well-Shield test is intended to help a clinician decide on invasive and/or non-invasive follow-up. It could help reduce the majority of the false positive results and reduce the number of unnecessary invasive procedures by more than 200,000 annually in the US (See footnotes (1) and (2)). As a result, Well-Shield's test could drive $3.6 billion in annual cost savings in the USA alone.
Footnotes: (1) Moving Beyond the National Lung Screening Trial: Discussing Strategies for Implementation of Lung Cancer Screening Programs Bernando H.L. Goulard, The Oncologist. 2013 Aug; 18(8): 941-946
(2) Assume 10 million patients screened and sensitivity and specificity of 92% and 75% respectively. Well-Shield may have higher or lower sensitivity and/or specificity.
Notice Regarding Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Forward-looking statements in this press release include that our technology is designed to be deployed for early detection of diseases; that our technology may have additional applications in drug response monitoring for therapies that impact immune response, that the Well-Shield™ technology is designed to detect and interpret differential metabolic responses. that Well-Shield could help reduce the majority of the false positive results and reduce the number of unnecessary invasive procedures by more than 200,000 annually in the US therefore could save $3.6 billion annually in the USA alone.; and that we have patent protection on our technology. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug and treatment discovery and development, which include, without limitation, the potential failure of development candidates to advance through clinical studies or demonstrate safety and efficacy in clinical testing; our ability to retain key employees; our ability to finance development; and our ability to satisfy the rigorous regulatory requirements for new medical procedures. Good results in small trials and among limited cases does not necessarily lead to the same good results for large numbers or in the general public. Competitors may develop better or cheaper alternatives to our products. Having patented technology does not guarantee that our patents may not be challenged, or that we may be infringing on the intellectual property of others. We may not be able to commercialize our product and even if we do, we may not realize any profit. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this press release to reflect events or circumstances after today's date. Readers should also refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.
December 16, 2015 14:11 ET
Online Disruptive Technologies Announces Approval to Perform Diagnostic Clinical Trials on Human Blood
LAS VEGAS, NEVADA--(Marketwired - Dec. 15, 2015) - Online Disruptive Technologies, Inc. (OTC PINK:ONDR) (the "Company") is pleased to announce that its majority owned Israeli subsidiary, Savicell Diagnostic Ltd. ("Savicell" ™), has received the approval of the Ethics Committee of the Institutional Review Board of the Rambam Health Care Campus to perform clinical trials on human blood for Savicell's blood test designed for the early diagnosis of lung cancer. The Rambam Health Care Campus is a 1,000-bed academic hospital serving the over 2 million residents of Northern Israel.
In addition, Savicell™ has received the approval of the Ethics Committee of the Institutional Review Board of the Meir Medical Center, also for human blood trials for lung cancer. This center represents a 717-bed hospital and serves as the central medical facility of the Sharon and Shomron area, serving a population of some 800,000 residents.
No further approvals are necessary to commence clinical trials for human blood tests for the detection of lung cancer at the Sourasky Medical Center or the Meir Medical Center. Savicell™ expects to expand its trials using blood supplied by these new sites during the month of December 2015.
Savicell™ has recently moved to a new, customized and larger lab in Haifa, Israel. The new facility will allow the company to handle an increased volume of testing and analysis.
Savicell™ is a company formed to commercialize a blood test uniquely designed for the early detection of diseases including cancer and auto-immune diseases.
Initially Savicell™ is focused on the multibillion-dollar cancer diagnosis market. Savicell™ deploys Well-Shield™ technology, an ImmunoBiopsy™ diagnostic platform. In contrast to existing technologies that evaluate secretions of cancer cells, Well-Shield's ImmunoBiopsy platform receives data directly from the immune system. Importantly, Well-Shield is different in that it is a functional test measuring the metabolic activation profile of the immune system as an indicator of disease status. As an immune system test it is inherently suited for early detection. The technology has intellectual property protection with a patent approved and published in the United States, with further international patent applications in process.
Disease intrusion and cell malformation, including cancer, are first detected by the immune system which energizes to rid the body of the malignancy. The initial immune response is intricate, deploying different metabolic pathways and subtypes of cells. A key function of immune system metabolic changes (glycolysis shifts) is to drive and control the effector function of the immune system. The effector ability to secrete disease-fighting cytokines (e.g. interferon gamma) is an example. The Savicell Well-Shield™ technology is designed to detect and interpret these differential metabolic responses.
Notice Regarding Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Forward-looking statements in this press release include that our unique technology is designed to be deployed for early detection of diseases; that we will expand our clinical trials on human blood this month; that we can handle an increased volume of analysis; and that we have patent protection on our technology. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development, which include, without limitation, the potential failure of development candidates to advance through clinical studies or demonstrate safety and efficacy in clinical testing; our ability to retain key employees; our ability to finance development; and our ability to satisfy the rigorous regulatory requirements for new medical procedures. Competitors may develop better or cheaper alternatives to our products. Having patented technology does not guarantee that our patents may not be challenged, or that we may be infringing on the intellectual property of others. We may not be able to commercialize our product and even if we do, we may not realize any profit. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this press release to reflect events or circumstances after today's date. Readers should also refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.